OmniAb (OABI) Current Assets (2021 - 2026)
OmniAb (OABI) reported Current Assets of $65.1 million for Q1 2026, up 21.55% year-over-year from $53.6 million in Q1 2025, and little changed on a QoQ basis from $65.3 million in Q4 2025.
OmniAb (OABI) has 6 years of Current Assets data on file, last reported at $65.1 million in Q1 2026.
- Quarterly Current Assets rose 21.55% year-over-year to $65.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.1 million (up 21.55% YoY) and the FY2025 annual result came in at $65.3 million, down 4.1% from the prior year.
- Current Assets was little changed at $65.1 million in Q1 2026 per OABI's latest filing, from $65.3 million in the prior quarter.
- Across five years, Current Assets topped out at $125.0 million in Q4 2022 and bottomed at $423868.0 in Q3 2022.
- The 5-year median for Current Assets is $66.6 million (2024), against an average of $67.2 million.
- The widest annual swing landed in 2022, when Current Assets slumped 65.88%; it then soared 25107.85% in 2023.
- Tracing OABI's Current Assets over 5 years: stood at $125.0 million in 2022, then retreated by 24.05% to $94.9 million in 2023, then retreated by 28.2% to $68.1 million in 2024, then decreased by 4.1% to $65.3 million in 2025, then fell by 0.33% to $65.1 million in 2026.
- Per Business Quant, the three latest OABI Current Assets figures stand at $65.1 million (Q1 2026), $65.3 million (Q4 2025), and $66.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 65.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.13 Mn |
| Dec 31, 2025 | 65.34 Mn |
| Sep 30, 2025 | 66.35 Mn |
| Jun 30, 2025 | 47.62 Mn |
| Mar 31, 2025 | 53.58 Mn |
| Dec 31, 2024 | 68.14 Mn |
| Sep 30, 2024 | 66.61 Mn |
| Jun 30, 2024 | 67.30 Mn |
| Mar 31, 2024 | 76.72 Mn |
| Dec 31, 2023 | 94.90 Mn |
| Sep 30, 2023 | 106.85 Mn |
| Jun 30, 2023 | 115.94 Mn |
| Mar 31, 2023 | 121.08 Mn |
| Dec 31, 2022 | 124.95 Mn |
| Sep 30, 2022 | 423,868.00 |
| Jun 30, 2022 | 692,011.00 |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 22.54 Mn |
| Sep 30, 2021 | 1.24 Mn |